At Reason, Nick Gillespie (“How to Build a Better Epi-Pen — or Something Totally Different That’s Much Better,” Sept. 4) argues — correctly — that Mylan’s EpiPen price-gouging is enabled by government regulations. He cites fellow Reason writer Scott Shackelford’s earlier article (“Want to Reduce the Price of Epipens? Approve Some Competition!” Aug. 25) showing…